YScope delivers a portable computer-aided sperm analysis (CASA) platform that transforms male reproductive health assessment. The technology combines pocket-sized hardware with specialized consumables to provide accurate motility and concentration analysis at significantly lower cost than traditional systems.
Currently CE-marked for veterinary applications with proven market traction (50+ users, 100k+ tests), YScope is positioned for human fertility applications through a defined regulatory pathway. The platform's modular architecture enables expansion beyond basic semen analysis through specialized consumables and AI-powered analytics.
The business model combines device sales with recurring consumable revenue, supported by patents through 2038 in key markets. Beyond fertility clinics and andrology practices, YScope's platform potential extends to sperm enhancement therapy monitoring and broader male health assessment applications.
Protected by patents through 2038 and validated through 10,000+ veterinary analyses, YScope is now available for exclusive human medical market expansion.
Contact Dr. Tamas Babel to access the complete due diligence package and discuss acquisition terms.